Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung Cancer

ended

Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds. The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery due to co-morbidities. Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system. The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval. This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes increase.